Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

• Status: Completed
• Trial end date: 2015-10-01

Summary

This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.

• Phase: Phase 3

Details

• Lead Sponsor: Mitsubishi Tanabe Pharma Corporation
• Collaborator: Toray Industries, Inc
• Treatments: Interferon-beta; Interferons